| Eye Central | |
|
8889 Jewella Ave, Ste C, Shreveport, LA 71118-2138 | |
| (318) 686-5227 | |
| (318) 686-5283 |
| Full Name | Eye Central |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 8889 Jewella Ave, Shreveport, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386044808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1775-709T (Louisiana) | Primary |
| Provider Name | Bradly Kendall Larson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1053729152 PECOS PAC ID: 3274856562 Enrollment ID: I20141217001051 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
| Provider Name | Zelmira M Farmer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1962954735 PECOS PAC ID: 2769730092 Enrollment ID: I20180802003056 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
| Provider Name | Naba Razi Khan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1114579554 PECOS PAC ID: 3173853553 Enrollment ID: I20190927000776 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
| Provider Name | Kyle Devon Andrus |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1316982028 PECOS PAC ID: 6709809692 Enrollment ID: I20210426000265 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
| Provider Name | Verle Judd |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1659943736 PECOS PAC ID: 9032598123 Enrollment ID: I20220621000809 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
| Provider Name | Weston Whitworth |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1083284129 PECOS PAC ID: 6709267388 Enrollment ID: I20220713002391 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eye Central 8889 Jewella Ave, Ste C, Shreveport, LA 71118-2138 Ph: (318) 686-5227 | Eye Central 8889 Jewella Ave, Ste C, Shreveport, LA 71118-2138 Ph: (318) 686-5227 |
News Archive
New details emerge about the cut to the health law's Prevention and Public Health Fund in the $1 trillion spending bill, but a jobless benefits extension in Congress stalls. In the meantime, a mental health plan pushed by President Obama will get spending bill funds.
World Vision commends the U.S. Senate for approving increases for hunger and developmental assistance for fiscal years 2008 and 2009 in the Supplemental Appropriations Act, including $850 million in the first year to address the global food crisis.
A new study in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), showed that patients with severe, early-onset COPD who continued to smoke had a risk of mortality that was almost three times that of patients who stopped smoking.
Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
› Verified 4 days ago
Sam R Silverblatt, Od Apmc Optometrist Medicare: Medicare Enrolled Practice Location: 1803 E 70th St, Shreveport, LA 71105 Phone: 318-798-4000 Fax: 318-798-4001 | |
Dr. Christine M Davis, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 955 Pierremont Rd Ste 400, Shreveport, LA 71106 Phone: 318-868-6118 Fax: 318-666-9927 | |
Look Eyecare Llc Optometrist Medicare: Medicare Enrolled Practice Location: 5848 Line Ave, Shreveport, LA 71106 Phone: 318-865-0017 | |
Lusk Eye Specialists, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 451 Ashley Ridge Blvd, Shreveport, LA 71106 Phone: 318-222-5555 Fax: 318-222-6414 | |
Dr. Bradly Kendall Larson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8889 Jewella Ave Ste C, Shreveport, LA 71118 Phone: 318-686-5227 Fax: 381-686-5283 | |
Weston Whitworth, OD Optometrist Medicare: Medicare Enrolled Practice Location: 8889 Jewella Ave, Shreveport, LA 71118 Phone: 318-686-5227 | |
Dr. Michael David Pickering, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5848 Line Ave, Shreveport, LA 71106 Phone: 318-865-0017 Fax: 318-868-4738 |